The Irradiation Facility at Fox Chase Cancer Center (FCCC) manages the shared use of ionizing radiation sources according to procedures mandated in our license from the Nuclear Regulatory Commission (NRC). Management and maintenance of these potentially dangerous, costly devices ($100,000-$200,000 each) as a shared resource for multiple users facilitates administration, quality assurance, safety and regulatory compliance. The Facility consists of two different irradiators, each sited optimally for its specific use. They produce fields of Cesium-137 gamma-rays to irradiate molecules in solution, cell cultures, rodent tumors or normal tissues for studies of radiobiologic mechanisms, to suppress immune response, to induce DMA damage and/or mitotic arrest, and to sterilize cell and drug preparations. The Shepherd Model 280 irradiator is situated in the Laboratory Animal Facility and used mainly for whole body irradiation of animals used in immunobiology research (see Hayakawa et al., J. Exp. Med. 197:87-99, 2003;Allman et al., J. Immunol. 167:6834-6840, 2001). The panoramic Shepherd Model 81-14R irradiator is situated in the basement of the Reimann Building. It was used 223 times in 2003 primarily for the irradiation of cells (see, for example, Katz et al., J. Virol. 76:5422-5434, 2002;Mu et al., Int. J. Radiat. Oncol. Biol. Phys. 58:336-343, 2004). Oversight of Facility operation is provided by the Facility Manager, Facility Director, Radiation Safety Officer, Radiation Safety Committee, FCCC Administration and the NRC. Facility staff operate various radiation dosimeters to accurately determine the dose to experimental set-ups and is available to FCCC investigators for planning radiation experiments, to assist infrequent users, for training individuals to become qualified irradiator users in accord with NRC and other safety regulations and for overseeing the annual maintenance and quality assurance of equipment. Inventories of the radioactive sources are made at intervals determined by the Homeland Security threat level. Over the last Core grant cycle, the Facility was used by 24 peer-reviewed funded investigators from ten FCCC research Programs in two Center Divisions. Currently, 92% of Facility use is by peer-reviewed funded investigators. Facility use has increased about 10% per year and is projected to increase 5-10% per year during the next Core grant cycle.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-47
Application #
7881784
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
47
Fiscal Year
2009
Total Cost
$64,481
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Golemis, Erica A; Scheet, Paul; Beck, Tim N et al. (2018) Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 32:868-902
Reese, Jennifer Barsky; Sorice, Kristen; Lepore, Stephen J et al. (2018) Patient-clinician communication about sexual health in breast cancer: A mixed-methods analysis of clinic dialogue. Patient Educ Couns :
Wagner, Jessica; Kline, C Leah; Zhou, Lanlan et al. (2018) Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. J Clin Invest 128:2325-2338
Araiza-Olivera, D; Feng, Y; Semenova, G et al. (2018) Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors. Oncogene 37:944-952
Fareed, Muhammad M; Eldib, Ahmed; Weiss, Stephanie E et al. (2018) A treatment planning comparison between a novel rotating gamma system and robotic linear accelerator based intracranial stereotactic radiosurgery/radiotherapy. Phys Med Biol 63:035029
Bleicher, Richard J (2018) Timing and Delays in Breast Cancer Evaluation and Treatment. Ann Surg Oncol 25:2829-2838
Bai, Tian; Chanda, Ashis Kumar; Egleston, Brian L et al. (2018) EHR phenotyping via jointly embedding medical concepts and words into a unified vector space. BMC Med Inform Decis Mak 18:123
Mehrazin, Reza; Dulaimi, Essel; Uzzo, Robert G et al. (2018) The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. Ther Adv Urol 10:3-10
Tang, Baiqing; Lee, Hyung-Ok; An, Serim S et al. (2018) Specific Targeting of MTAP-Deleted Tumors with a Combination of 2'-Fluoroadenine and 5'-Methylthioadenosine. Cancer Res 78:4386-4395
Fang, Carolyn Y; Tseng, Marilyn (2018) Ethnic density and cancer: A review of the evidence. Cancer 124:1877-1903

Showing the most recent 10 out of 1280 publications